Velsera is a precision medicine technology company that accelerates the discovery, development, and delivery of life-changing insights through integrated AI-enhanced software and expert services. Formed in 2023 through the merger of Seven Bridges, PierianDx, and UgenTec, Velsera combines over two decades of experience working with leading diagnostic and pharma partners to solve cutting-edge problems in genomics and clinical diagnostics.
The company partners with life science and clinical diagnostic organizations to provide multimodal data harmonization and analytics for drug discovery and development, IVD development and regulatory approval, and clinical NGS interpretation and reporting. Velsera's platform includes the Seven Bridges bioinformatics environment, Clinical Genomics Workspace, ARIA data harmonization platform, and an IVD-grade Knowledgebase for variant interpretation. With operations in the US, Europe, and Asia, Velsera serves top pharmaceutical companies, clinical diagnostic laboratories, NGS assay manufacturers, and non-profit organizations, processing over 250,000 NGS samples annually and supporting 80+ active clinical NGS lab customers.
